--- title: "Biodexa Pharmaceuticals (BDRX) news: offering" url: "https://aibio.space/companies/biodexa-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BDRX offering news: Biodexa prices $10 million best-efforts offering of ADS units and warrants. Biodexa Pharmaceuticals plc (NASDAQ: BDRX), United Kingdom." --- BDRX Biodexa Pharmaceuticals plc NASDAQ · United Kingdom # Biodexa Pharmaceuticals (BDRX) news BDRX offering news Listings · 2026-10-08 ## [Biodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split](https://aibio.space/news/biodexa-changes-ads-ratio-400-ordinary-shares-one-eight-reverse-ads/) The exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change. ## Latest Biodexa Pharmaceuticals news 1. 2026-03-18 Listings [Biodexa to change ADR ratio to 500,000 shares, a one-for-five reverse ADR split](https://aibio.space/news/biodexa-change-adr-ratio-500-000-shares-one-five-reverse-adr-split/) The change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work. 2. 2025-12-18 Financings [Biodexa prices $10 million best-efforts offering of ADS units and warrants](https://aibio.space/news/biodexa-prices-10-million-best-efforts-offering-ads-units-warrants/) Biodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025. 3. 2025-11-17 Financings [Biodexa Pharmaceuticals plans offering of up to 3,377,110 ADS-and-warrant units](https://aibio.space/news/biodexa-pharmaceuticals-plans-offering-up-3-377-110-ads-warrant-units/) The best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised. ## Biodexa Pharmaceuticals at a glance - **Ticker**: BDRX - **Listing**: NASDAQ - **Country**: United Kingdom ### Related companies - [Haleon](https://aibio.space/companies/haleon/) LSE: HLN - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) NASDAQ: BCYC - [Roivant Sciences](https://aibio.space/companies/roivant-sciences/) NASDAQ: ROIV - [Arecor Therapeutics](https://aibio.space/companies/arecor-therapeutics/) LSE: AREC - [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) NASDAQ: KNSA - [Coiled Therapeutics Plc](https://aibio.space/companies/coiled-therapeutics/) LSE: COIL - [Shield Therapeutics Plc](https://aibio.space/companies/shield-therapeutics/) LSE: STX - [ValiRx](https://aibio.space/companies/valirx/) LSE: VAL ### Also on NASDAQ - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) KYTX - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) ELVN - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) TARA - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) INDP ## What Biodexa Pharmaceuticals does Biodexa Pharmaceuticals plc is a clinical stage biopharmaceutical company developing products for the treatment or prevention of gastrointestinal cancers, including gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP). It was originally formed in England and Wales in 2000 as Midatech Ltd, with a gold nanoparticle drug delivery platform. Its lead product, eRapa, is a proprietary formulation of rapamycin, an mTOR inhibitor, licensed in April 2024 from Rapamycin Holdings, Inc., d/b/a Emtora Biosciences, Inc. The Phase 3 study of eRapa in FAP is a double-blind, placebo-controlled trial in 168 patients, randomized 2:1 drug to placebo, conducted in approximately 30 clinical sites across the United States and Europe. As of March 16, 2026, there were 22 active clinical sites and 37 patients enrolled. The FDA granted fast track designation for eRapa on February 10, 2025. A Phase 2 study of eRapa in NMIBC is ongoing as an investigator-run trial at the University of Texas, San Antonio. On February 4, 2026, the company licensed MTX240, a molecular glue that it intends to develop initially for GIST, from Otsuka Pharmaceutical Co., Ltd. | Product or program | What it is | Stage | |---|---|---| | eRapa | Proprietary rapamycin formulation for familial adenomatous polyposis and NMIBC | Phase 3 in FAP; Phase 2 in NMIBC | | MTX240 | Molecular glue for gastrointestinal stromal tumors, licensed from Otsuka | Phase 1b/2a dose escalation planned after IND | Summarised from the company's [20-F filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1643918/000121465926003921/bp31726520f.htm). ## Questions about Biodexa Pharmaceuticals Has Biodexa Pharmaceuticals raised money recently? Our latest story on this, dated Dec 18, 2025: "Biodexa prices $10 million best-efforts offering of ADS units and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biodexa-prices-10-million-best-efforts-offering-ads-units-warrants/). What is the ticker symbol of Biodexa Pharmaceuticals? Biodexa Pharmaceuticals plc trades under the ticker BDRX on NASDAQ. Where is Biodexa Pharmaceuticals listed? Biodexa Pharmaceuticals plc is listed on NASDAQ. What is the SEC CIK of Biodexa Pharmaceuticals? The SEC Central Index Key (CIK) for Biodexa Pharmaceuticals plc is 1643918. Its filings are on SEC EDGAR. How many shares does Biodexa Pharmaceuticals have outstanding? 225,817,808,922 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-27. Which country or territory is Biodexa Pharmaceuticals listed under? Our directory records Biodexa Pharmaceuticals plc under United Kingdom. What does Biodexa Pharmaceuticals do? Our directory classifies Biodexa Pharmaceuticals plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Biodexa Pharmaceuticals? The ISIN recorded for Biodexa Pharmaceuticals plc is US59564R8723. Does aibio.space cover Biodexa Pharmaceuticals? aibio.space lists Biodexa Pharmaceuticals plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Biodexa Pharmaceuticals incorporated? SEC records list its state or country of incorporation as X0. What does Biodexa Pharmaceuticals develop? Biodexa Pharmaceuticals plc is a clinical stage biopharmaceutical company developing products for the treatment or prevention of gastrointestinal cancers, including gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP). It was originally formed in England and Wales in 2000 as Midatech Ltd, with a gold nanoparticle drug delivery platform. What is eRapa from Biodexa Pharmaceuticals? eRapa: Proprietary rapamycin formulation for familial adenomatous polyposis and NMIBC Stage: Phase 3 in FAP; Phase 2 in NMIBC. What is MTX240 from Biodexa Pharmaceuticals? MTX240: Molecular glue for gastrointestinal stromal tumors, licensed from Otsuka Stage: Phase 1b/2a dose escalation planned after IND. What is the latest Biodexa Pharmaceuticals (BDRX) stock news? Our latest story on Biodexa Pharmaceuticals, dated Oct 8, 2026: "Biodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split". The exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change. [Source](https://aibio.space/news/biodexa-changes-ads-ratio-400-ordinary-shares-one-eight-reverse-ads/). How long will Biodexa Pharmaceuticals's cash last? From our story of Dec 18, 2025: The auditor's report on the 2024 financial statements, from PKF Littlejohn LLP, contains an explanatory paragraph about the company's ability to continue as a going concern. [Source](https://aibio.space/news/biodexa-prices-10-million-best-efforts-offering-ads-units-warrants/). ## Investor discussion: Biodexa Pharmaceuticals Members talk about Biodexa Pharmaceuticals (BDRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Biodexa Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-08 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465926012706/g1082626k.htm) 2. 2026-07-29 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465926009162/ex99_1.htm) 3. 2026-05-14 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465926006195/ex99_1.htm) 4. 2026-03-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465926003454/ex99_1.htm) 5. 2025-12-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465925018196/ex99_1.htm) 6. 2025-11-17 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465925016821/p9262512f1.htm) 7. 2025-07-31 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000117184325004878/exh_991.htm) 8. 2025-07-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465925010428/ex99_1.htm) 9. 2025-01-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465925000919/y1162546k.htm) 10. 2024-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1643918/000121465924018699/ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BDRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-BDRX/). ## SEC filings and registration - **SEC name**: Biodexa Pharmaceuticals Plc - **CIK**: 1643918 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BDRX (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 1 CASPIAN POINT, CARDIFF, CF10 4DQ - **Phone**: 44 (0)1235 888300 - **Shares outstanding**: 225,817,808,922 as of 2025-12-31 (20-F filed 2026-03-27) - **Former names**: Midatech Pharma Plc ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000117184326006616/f6k_101426.htm) filed 2026-10-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000121465926012706/g1082626k.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000121465926011688/i9142616k.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000121465926011630/w9102626k.htm) filed 2026-09-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000121465926009162/z7272616k.htm) filed 2026-07-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000121465926008398/w792616k.htm) filed 2026-07-09 - [424B5](https://www.sec.gov/Archives/edgar/data/1643918/000121465926007998/g630263424b5.htm) filed 2026-07-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1643918/000117184326004399/f6k_063026.htm) filed 2026-06-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001643918), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Biodexa Pharmaceuticals plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BDRX, recorded under United Kingdom. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Biodexa Pharmaceuticals plc - **Ticker**: BDRX - **Listing**: NASDAQ - **Country or territory**: United Kingdom - **Business scope**: Pharmaceuticals: Major - **ISIN**: US59564R8723 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BDRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biodexa-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biodexa Pharmaceuticals (BDRX) news: offering", 2026-10-31, https://aibio.space/companies/biodexa-pharmaceuticals/